Progress of hematologic malignancy related gene mutations in patients with chronic myelogenous leukemia

VernacularTitle:慢性粒细胞白血病患者血液肿瘤相关基因突变研究进展
Author: Lan YANG ¹ ; Lixia CAO ; Huijuan REN ; Yanqiu HAN
Author Information

1. 内蒙古医科大学附属医院血液科，呼和浩特　010050
Keywords: Leukemia, myelogenous, chronic, BCR-ABL positive; Genes; Mutation; Tyrosine kinase inhibitors
From: Journal of Leukemia & Lymphoma 2021;30(11):701-704
CountryChina
Language:Chinese
Abstract: Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by heterotopic Ph chromosome. Tyrosine kinase inhibitor (TKI) has significantly improved the prognosis of patients with CML. Cytogenetic and molecular monitoring for assessing the therapeutic efficacy of TKI to guide disease management has become an important component of CML therapy. However, the expanded genomic analysis of the disease diagnosis, transformation and drug resistance has not been fully explored in CML research. The paper reviews the frequency and type of gene mutations at initial diagnosis and the time of treatment failure and transformation, and investigates the relationship between genetic mutations and the prognosis of CML patients in the diagnosis and treatment.